This content is only available within our institutional offering.
08 Sep 2015
TuzistraTM XR launched in the US
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
TuzistraTM XR launched in the US
The launch of the group’s lead cough cold product, TuzistraTM XR, in the US following FDA approval in April is a key development for Vernalis. We re-iterate our Buy recommendation and 93p target price.